Issues on peritoneal metastasis of gastric cancer: an update
- PMID: 31829265
- PMCID: PMC6907197
- DOI: 10.1186/s12957-019-1761-y
Issues on peritoneal metastasis of gastric cancer: an update
Abstract
Background: Peritoneal metastasis (PM) is one of the most common forms of metastasis with a very poor prognosis in patients with gastric cancer (GC). The mechanisms, diagnosis, and management of PM remain controversial.
Main body: Stephen Paget's "seed-and-soil" hypothesis gives us an illustration of the mechanisms of PM. Recently, hematogenous metastasis and exosomes from GC are identified as novel mechanisms for PM. Diagnostic accuracy of conventional imaging modalities for PM is not satisfactory, but texture analysis may be a useful adjunct for the prediction of PM. Biological markers in peritoneal washings are helpful in identifying patients at high risk of PM, but many limitations remain to be overcome. Response of PM from systemic chemotherapy alone is very limited. However, conversion therapy is confirmed to be safe and able to prolong the survival of GC patients with PM. As an important part of conversion therapy, intraperitoneal chemotherapy with taxanes has become an ideal approach with several advantages. Additionally, gastrectomy should be considered in patients who would tolerate surgery if a remarkable response to chemotherapy was observed.
Conclusion: Texture analysis is a reliable adjunct for the prediction of PM, and conversion therapy provides a new choice for GC patients with PM. The underlying mechanisms and new biological markers for GC patients with PM should be the direction of future studies. Furthermore, significant aspects of conversion therapy, such as timing and method of the operation, and the indications remain to be clarified.
Keywords: Conversion therapy; Diagnosis; Gastric cancer; Intraperitoneal chemotherapy; Peritoneal metastasis.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.Gastric Cancer. 2017 Mar;20(Suppl 1):128-134. doi: 10.1007/s10120-016-0684-3. Epub 2016 Dec 27. Gastric Cancer. 2017. PMID: 28028665
-
Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis: A Meta-Analysis.J Surg Res. 2020 Jan;245:234-243. doi: 10.1016/j.jss.2019.07.044. Epub 2019 Aug 14. J Surg Res. 2020. PMID: 31421368
-
Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer.Gastric Cancer. 2023 May;26(3):364-378. doi: 10.1007/s10120-023-01368-3. Epub 2023 Feb 4. Gastric Cancer. 2023. PMID: 36738390
-
Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis.Surg Oncol Clin N Am. 2018 Jul;27(3):519-537. doi: 10.1016/j.soc.2018.02.006. Surg Oncol Clin N Am. 2018. PMID: 29935687 Review.
-
[Clinical significance and practice points of conversion therapy for gastric cancer with peritoneal metastasis].Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Oct 25;20(10):1094-1098. Zhonghua Wei Chang Wai Ke Za Zhi. 2017. PMID: 29130218 Review. Chinese.
Cited by
-
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.BMC Cancer. 2023 Oct 25;23(1):1032. doi: 10.1186/s12885-023-11549-z. BMC Cancer. 2023. PMID: 37875869 Free PMC article. Clinical Trial.
-
Efficacy analysis of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer: a retrospective study.Front Oncol. 2025 Jan 9;14:1503045. doi: 10.3389/fonc.2024.1503045. eCollection 2024. Front Oncol. 2025. PMID: 39850825 Free PMC article.
-
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data.Signal Transduct Target Ther. 2024 Aug 26;9(1):222. doi: 10.1038/s41392-024-01932-y. Signal Transduct Target Ther. 2024. PMID: 39183247 Free PMC article.
-
Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.Gastric Cancer. 2024 Mar;27(2):387-399. doi: 10.1007/s10120-023-01452-8. Epub 2023 Dec 24. Gastric Cancer. 2024. PMID: 38143257 Free PMC article.
-
High FAM189B Expression and Its Prognostic Value in Patients with Gastric Cancer.Biomed Res Int. 2021 May 25;2021:8875971. doi: 10.1155/2021/8875971. eCollection 2021. Biomed Res Int. 2021. PMID: 34124264 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous